BAL PHARMA Financial Statement Analysis
|
||
The Revenues of BAL PHARMA have decreased by -10.65% YoY .
The Earnings Per Share (EPS) of BAL PHARMA has decreased by -3.21 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
BAL PHARMA Last 5 Annual Financial Results
[BOM: 524824|NSE : BALPHARMA]
Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
---|---|---|---|---|---|
Revenues | ₹303 Cr | ₹339 Cr | ₹304 Cr | ₹281 Cr | ₹251 Cr |
Expenses | ₹273 Cr | ₹308 Cr | ₹279 Cr | ₹257 Cr | ₹226 Cr |
Operating Profit (Excl OI) | ₹30 Cr | ₹31 Cr | ₹25 Cr | ₹24 Cr | ₹25 Cr |
Other Income | ₹2.20 Cr | ₹2.85 Cr | ₹0.94 Cr | ₹5.15 Cr | ₹1.14 Cr |
Interest | ₹17 Cr | ₹15 Cr | ₹12 Cr | ₹11 Cr | ₹12 Cr |
Depreciation | ₹9.77 Cr | ₹10 Cr | ₹9.13 Cr | ₹9.04 Cr | ₹9.52 Cr |
Profit Before Tax | ₹5.14 Cr | ₹9.05 Cr | ₹4.75 Cr | ₹9.18 Cr | ₹4.10 Cr |
Profit After Tax | ₹7.24 Cr | ₹7.45 Cr | ₹2.62 Cr | ₹5.71 Cr | ₹4.71 Cr |
Consolidated Net Profit | ₹7.22 Cr | ₹7.39 Cr | ₹2.57 Cr | ₹5.61 Cr | ₹4.74 Cr |
Earnings Per Share (Rs) | ₹4.53 | ₹4.68 | ₹1.64 | ₹3.79 | ₹3.20 |
PAT Margin (%) | 2.39 | 2.19 | 0.86 | 2.03 | 1.88 |
ROE(%) | 9.69 | 10.97 | 4.31 | 10.34 | 8.97 |
ROCE(%) | 10.10 | 11.67 | 9.56 | 12.33 | 9.72 |
Total Debt/Equity(x) | 1.94 | 1.94 | 2.05 | 1.80 | 2.09 |
Key Financials |
||
Market Cap | : | ₹ 131.6 Cr |
Revenue (TTM) | : | ₹ 294.6 Cr |
Net Profit(TTM) | : | ₹ 7.2 Cr |
EPS (TTM) | : | ₹ 4.5 |
P/E (TTM) | : | 18.3 |
Industry Peers & Returns | 1W | 1M | 1Y |
BAL PHARMA | -3.5% | -3.1% | -31.8% |
SUN PHARMACEUTICAL INDUSTRIES | -3.5% | 0% | -12.9% |
DIVIS LABORATORIES | -6.6% | -7.2% | 9.8% |
CIPLA | -2.8% | -5% | -7.8% |
TORRENT PHARMACEUTICALS | -2.5% | -0.4% | 1.7% |
DR REDDYS LABORATORIES | -3.8% | -0.6% | -4.2% |
MANKIND PHARMA | -4.4% | 0.3% | -7.7% |
ZYDUS LIFESCIENCES | -5.7% | -0.1% | -3.1% |
LUPIN | -4.2% | 1% | -11.4% |
BAL PHARMA Revenues
[BOM: 524824|NSE : BALPHARMA]
Y-o-Y | -10.65 % |
5 Yr CAGR | 4.88 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹303 Cr | -10.65 | |
Mar2024 | ₹339 Cr | 11.51 | |
Mar2023 | ₹304 Cr | 8.18 | |
Mar2022 | ₹281 Cr | 12.25 | |
Mar2021 | ₹251 Cr | - |
BAL PHARMA Operating Profit
[BOM: 524824|NSE : BALPHARMA]
Y-o-Y | -3.80 % |
5 Yr CAGR | 4.83 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹30 Cr | -3.80 | |
Mar2024 | ₹31 Cr | 22.52 | |
Mar2023 | ₹25 Cr | 5.30 | |
Mar2022 | ₹24 Cr | -2.70 | |
Mar2021 | ₹25 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 7.68 % |
5 Yr CAGR | -0.05 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 9.82% | 7.68 | |
Mar2024 | 9.12% | 9.88 | |
Mar2023 | 8.3% | -2.70 | |
Mar2022 | 8.53% | -13.31 | |
Mar2021 | 9.84% | - |
BAL PHARMA Profit After Tax
[BOM: 524824|NSE : BALPHARMA]
Y-o-Y | -2.39 % |
5 Yr CAGR | 11.06 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹7.22 Cr | -2.39 | |
Mar2024 | ₹7.39 Cr | 187.40 | |
Mar2023 | ₹2.57 Cr | -54.17 | |
Mar2022 | ₹5.61 Cr | 18.35 | |
Mar2021 | ₹4.74 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 9.13 % |
5 Yr CAGR | 6.18 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 2.39 % | 9.13 | |
Mar2024 | 2.19 % | 154.65 | |
Mar2023 | 0.86 % | -57.64 | |
Mar2022 | 2.03 % | 7.98 | |
Mar2021 | 1.88 % | - |
BAL PHARMA Earnings Per Share (EPS)
[BOM: 524824|NSE : BALPHARMA]
Y-o-Y | -3.21 % |
5 Yr CAGR | 9.08 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹4.53 | -3.21 | |
Mar2024 | ₹4.68 | 185.37 | |
Mar2023 | ₹1.64 | -56.73 | |
Mar2022 | ₹3.79 | 18.44 | |
Mar2021 | ₹3.20 | - |
BAL PHARMA Return on Capital Employed (ROCE)
[BOM: 524824|NSE : BALPHARMA]
Y-o-Y | -13.45 % |
5 Yr CAGR | 0.96 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2025 | 10.1% | -13.45 | |
Mar2024 | 11.67% | 22.07 | |
Mar2023 | 9.56% | -22.47 | |
Mar2022 | 12.33% | 26.85 | |
Mar2021 | 9.72% | - |
BAL PHARMA Share Price vs Sensex
Current Share Price | : | ₹82.8 |
Current MarketCap | : | ₹ 131.6 Cr |
Updated EOD on | : | Sep 26,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
BAL PHARMA | -3.5% |
-3.1% |
-31.8% |
SENSEX | -2.7% |
-0.5% |
-5.3% |
BAL PHARMA related INDICES
You may also like the below Video Courses
FAQ about BAL PHARMA Financials
How the annual revenues of BAL PHARMA have changed ?
The Revenues of BAL PHARMA have decreased by -10.65% YoY .
How the Earnings per Share (EPS) of BAL PHARMA have changed?
The Earnings Per Share (EPS) of BAL PHARMA has decreased by -3.21 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs